OTC Markets OTCPK - Delayed Quote USD

PeptiDream Inc. (PPTDF)

17.85

0.00

(0.00%)

At close: January 29 at 3:00:00 PM EST

PeptiDream Announces Second Internal Peptide Radiopharmaceutical Therapeutic Program Targeting Claudin 18.2 for the Potential Diagnosis and Treatment of Gastric Cancer

KAWASAKI, Japan, December 12, 2024--We are planning to initiate human Ph0 imaging studies of 64Cu-PD-29875, highly-selective peptide-RI conjugate against Claudin 18.2, in 2025.

Business Wire last month

PPTDF
0.00%
PeptiDream Announces Preclinical Results Demonstrating Efficacy of Oral Myostatin Inhibitors in Preventing Loss of Lean Mass Associated with Semaglutide Treatment

KAWASAKI, Japan, December 12, 2024--PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter "PeptiDream")(Tokyo: 4587) today announced the highly promising results from the preclinical testing of the company’s oral myostatin inhibitors, administered in combination with semaglutide (a GLP-1 receptor agonist; a class of molecules known for the ability to aid in weight loss by modulating appetite and promoting satiety) in a mice model of ob

Business Wire last month

PPTDF
0.00%
NorthStar Medical Radioisotopes and PDRadiopharma Announce Research and Development Agreement, Master Isotope Supply Agreement for Ac-225 and Contract Manufacturing and Master Services Agreement

BELOIT, Wis. & KAWASAKI, Japan, December 05, 2024--NorthStar Medical Radioisotopes, LLC, and PeptiDream Inc. (President: Patrick C. Reid, Tokyo: 4587) today announced that PeptiDream’s wholly owned subsidiary PDRadiopharma Inc. (President: Masato Murakami) has entered into a strategic collaboration with NorthStar, a global innovator in the development, production, and commercialization of radiopharmaceuticals used for therapeutic applications and medical imaging. PDRadiopharma is the leading rad

Business Wire last month

PPTDF
0.00%
NCC and PeptiDream Announce the First Dosing of 64Cu-PD-32766 in a patient with Clear Cell Renal Cell Carcinoma

KAWASAKI, Japan, June 04, 2024--National Cancer Center and PeptiDream Inc.:

Business Wire 7 months ago

PPTDF
0.00%
PeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis

KAWASAKI, Japan, April 30, 2024--PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President and CEO: Patrick C. Reid, hereinafter "PeptiDream") (Tokyo: 4587) today announced an expansion of its peptide discovery collaboration with Swiss-based Novartis Pharma AG ("hereinafter Novartis") (NYSE: NVS). Under the multi-program agreement, PeptiDream will use its proprietary Peptide Discovery Platform System ("PDPS®") technology to identify and optimize novel macrocyclic pepti

Business Wire 8 months ago

PPTDF
0.00%

Performance Overview

Return	PPTDF	Nikkei 225
YTD	0.00%	-0.60%
1-Year	+108.53%	+9.28%
3-Year	-5.71%	+46.86%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

PeptiDream Inc. (PPTDF)

PeptiDream Announces Second Internal Peptide Radiopharmaceutical Therapeutic Program Targeting Claudin 18.2 for the Potential Diagnosis and Treatment of Gastric Cancer

PeptiDream Announces Preclinical Results Demonstrating Efficacy of Oral Myostatin Inhibitors in Preventing Loss of Lean Mass Associated with Semaglutide Treatment

NorthStar Medical Radioisotopes and PDRadiopharma Announce Research and Development Agreement, Master Isotope Supply Agreement for Ac-225 and Contract Manufacturing and Master Services Agreement

NCC and PeptiDream Announce the First Dosing of 64Cu-PD-32766 in a patient with Clear Cell Renal Cell Carcinoma

PeptiDream Announces Expansion of Peptide Discovery Collaboration with Novartis

Performance Overview